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Purpose: To compare clinical outcomes in a prospective trial of cataract surgery patients 
bilaterally implanted with two different trifocal intraocular lenses (IOLs) with very similar 
optical designs but consisting of different IOL materials (hydrophobic and hydrophilic).
Patients and Methods: Fifty-one patients (102 eyes) were randomized to receive trifocal 
IOLs bilaterally – FineVision POD F (hydrophilic) or FineVision POD F GF (hydrophobic) 
(both PhysIOL, Liége, Belgium). The follow-up period was 3 months. Outcome measurements 
included uncorrected distance (UDVA), corrected distance (CDVA), distance-corrected inter-
mediate (DCIVA), and distance-corrected near visual acuity (DCNVA), refraction, negative 
dysphotopsia, optical quality of vision, contrast sensitivity under photopic and mesopic con-
ditions, halometry (discrimination index), and patient-reported outcomes.
Results: At the final study visit, mean (SD) values for binocular UDVA, CDVA, DCIVA 
(80 cm), and DCNVA (40 cm) were −0.01 (0.06), −0.04 (0.04), 0.09 (0.10), and 0.10 (0.09) 
logMAR, respectively, for POD F, and 0.01 (0.08), −0.03 (0.03), 0.08 (0.1), and 0.13 (0.11) 
respectively, for POD F GF. Defocus assessments showed a continuous curve with 
a functional range of visual acuity (≤0.15 logMAR) from ~30 cm to infinity in both groups. 
The discrimination index was >0.85 for all patients, and both groups showed similar contrast 
sensitivity under photopic and mesopic conditions. At 3 months, no patient reported negative 
dysphotopsia, and high satisfaction rates were observed.
Conclusion: Clinical outcomes showed no significant difference between each lens when 
measured at 1 month and 3 months after implantation. This equally good clinical perfor-
mance of hydrophilic and hydrophobic trifocal lenses allows the surgeon to choose the IOL 
material based on personal preferences or patients’ needs.
Keywords: trifocal FineVision, intraocular lens, biomaterial, hydrophobic, hydrophilic, 
glistening-free
Introduction
It is often said that “cataract surgery is refractive surgery”. The advances in 
intraocular lens (IOL) design over the previous two decades have resulted in 
many patients choosing multifocal rather than monofocal lens implants to enable 
good vision not only at far but also at intermediate and near distances, so they have 
reduced or no spectacle dependence after surgery. However, with multifocal dif-
fractive lens designs, multiple images are displayed on the retina and neuroadapta-
tion is required for the patient to “focus”. There are various optical compromises 
that are made with multifocal IOLs when compared to monofocal lenses; for 
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example, reduced contrast sensitivity and photic 
phenomena.1,2 Careful patient and lens selection, meticu-
lous ocular biometry measurements and surgical precision 
are all pivotal in providing patients with the best possible 
visual outcome and greater spectacle independence.
Several factors after surgery can change patients’ 
visual outcomes and satisfaction, like lens tilt, rotation 
(in terms of toric IOLs), decentration, posterior capsular 
opacification (PCO) and glistenings. Many of the former 
phenomena can be mitigated through thoughtful lens and 
haptic design, but glistenings – fluid-filled microvacuoles 
that form within certain IOLs after implantation, and can 
develop in various shapes, sizes, and density – are 
a function of the material used. PCO is partly a function 
of IOL design (square optic edges that fit flush with the 
capsular bag reduces the rate of PCO) but also of IOL 
material.3,4 IOLs made from hydrophobic acrylic are asso-
ciated with an enhanced risk of glistening formation, but 
usually provoke low or no PCO,5 whereas hydrophilic 
IOLs resist glistening formation, but are more likely to 
develop PCO.6,7
In recent years, glistening-free (GF) hydrophobic IOL 
materials have been developed, and several IOLs made 
from GF materials have made it to the market. One IOL 
that has been marketed in Europe since 2010, the 
FineVision lens (POD F; PhysIOL, Liège, Belgium) is 
made from a 26% hydrophilic acrylic material with 
a trifocal optical design that combines two diffractive 
patterns; a +3.50 diopter (D) addition for near and 
a +1.75 D addition for intermediate vision, with the dif-
fractive steps being alternated over the optical zone. 
Several studies have shown that the POD F IOL offers 
a significant improvement in uncorrected visual acuity 
across all distances and high patient satisfaction.8–14
PhysIOL subsequently developed the POD F GF IOL, 
which retains the FineVision optic and the POD haptic 
design but differs in terms of the material as it is made 
from a hydrophobic acrylic glistening-free material called 
GFree.15
Given the two materials differ in refractive properties, 
the Abbe number (POD F GF: 42; POD F: 58) and the 
refractive index (POD F GF: 1.52; POD F: 1.46), the 
thickness of the optics of the POD F and POD F GF 
IOL are very different. However, the diffractive pattern 
of both lenses has been designed so that the measurable 
properties, such as near addition powers, are almost iden-
tical on the optical bench.
The goal of this current study was to compare visual 
and refractive outcomes between the hydrophobic trifocal 
POD F GF and the hydrophilic trifocal POD F IOL, and to 
investigate whether the newer POD F GF can achieve 
clinical outcomes comparable to its hydrophilic 
counterpart.8–14 Although monocular clinical results have 
been previously reported,9 to our knowledge, this is the 
first study reporting binocular clinical outcomes and 
patient satisfaction after POD F GF IOL implantation.
Patients and Methods
This was a prospective, randomized, controlled, single- 
surgeon (FP), single-center post-market clinical follow-up 
study (NCT03347981), performed at our eye clinic 
(Miranza, IOA Madrid, Spain). Informed consent and per-
mission to use their data for analysis and publication were 
obtained from each patient prior to surgery as part of our 
routine preoperative protocol. The study was conducted in 
accordance with the tenets of the Declaration of Helsinki 
and was approved by the ethics committee of the Hospital 
Clínico San Carlos (Madrid, Spain), Comité Ético de 
Investigación Clínica GAE HCSC Area 7 (C.I. 17/ 
165-R_P).
The study population comprised patients with cataracts 
and no other ocular comorbidities who spontaneously 
reported a desire for reduced spectacle dependence after 
surgery, and who were available, capable, and willing to 
comply with the study examination procedures. Patients 
were excluded if they were aged <45 years, had irregular 
astigmatism, regular corneal astigmatism >1.00 D or >1.50 
D if the steep cylinder axis was between 90 and 120 
degrees in one or both eyes. A history of ocular trauma 
or prior ocular surgery, and any ocular comorbidities, 
including capsule, zonule, pupil, and retina abnormalities 
or the expectation of complicated surgery served as exclu-
sion criteria.
All patients underwent a comprehensive preoperative 
ophthalmic examination, which included keratometry and 
biometry using the IOLMaster 700 (Carl Zeiss Meditec 
AG, Jena, Germany), intraocular pressure (IOP) using 
Goldmann applanation tonometry, fundus optical coher-
ence tomography (OCT) imaging (Cirrus; Carl Zeiss 
Meditec AG, Jena, Germany), manifest refraction, and 
pupil diameter measurements under photopic and mesopic 
conditions using the OPD Scan III (Nidek, Japan). The 
OPD Scan III was also used to perform aberrometry mea-
surements of spherical aberrations (SA), higher-order aber-
rations (HOA) and IOL tilt.
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Patients were scheduled to undergo routine femtose-
cond laser-assisted cataract surgery. The capsulotomy and 
the lens fragmentation were performed with the Catalys 
Precision system (Johnson & Johnson Vision, Santa Ana, 
California, USA). Then, a 2.2 mm 45-degree angled, 
bevel-up surgical knife (Xstar Safety Slit Knife, Beaver- 
Visitec International) was used to create a self-sealing 
clear corneal incision on the steep meridian. All the IOLs 
were implanted with one injector (Accujet 2.1, Medicel, 
Switzerland) to standardize the surgically induced astig-
matism, and capsular tension rings were used in most 
cases to increase the stability of the IOL. The optic- 
haptic junctions of the IOLs were placed inferotemporally 
in order to reduce negative dysphotopsias.16 IOL power 
calculation was performed using the Barrett formula and 
the following lens factors: 1.89 for POD F (already opti-
mized), and 2.09 for POD F GF. During the course of the 
study, we individualized the POD F GF lens factor result-
ing in a final value of 2.15.
Patients were assigned to one of two groups according 
to a randomization table: the study group (patients 
received the trifocal hydrophobic FineVision POD F GF 
IOL) and the control group (patients received the trifocal 
hydrophilic FineVision POD F IOL).
At the 3-month follow-up, UDVA, and CDVA at 
4 m (ETDRS [Early Treatment Diabetic Retinopathy 
Study] charts), DCIVA at 80 cm (Radner reading charts), 
and DCNVA at 40 cm (Radner reading charts) were bino-
cularly assessed, as were DCIVA at 70 cm and 35 cm 
(both ETDRS) at the 1-month follow-up.
Distance corrected visual acuities (CDVA, DCIVA, 
DCNVA) were measured using the subjective refraction 
for far distance. The Optical Quality Analysis System 
(OQAS) (Visiometrics S.L., Spain) was used to measure 
the Objective Scatter Index (OSI score), the Modulation 
transfer function (MTF) and the Strehl Ratio. Halometry 
was assessed using a bright light to dazzle a screen and the 
number of halos was determined by the number of cor-
rectly read characters, with the results expressed by the 
software package Halo v1.0 (University of Granada, 
Granada, Spain) as a “discrimination index.”
Defocus curves were generated by adding a defocus 
lens to the best-corrected refraction (at 4 m) from +2.0 
D to −4.0 D in steps of 0.5 D.
Contrast sensitivity was assessed under photopic (85 
cd/m2) and mesopic (3.5 cd/m2) light conditions using the 
Vector Vision CSV-1000 (VectorVision, Greenville, Ohio) 
system; mesopic contrast sensitivity was assessed by pla-
cing mesopic filters in the trial frame.
To assess subjective patient satisfaction, 
a questionnaire was handed out to the patients at the 
final examination visit. The questionnaire used was the 
validated National Eye Institute Visual Function 
Questionnaire-25 (NEI VFQ-25 questionnaire).17 In addi-
tion, to evaluate the rate of negative dysphotopsia, the 
patients were asked directly whether they perceive a dark 
shadow in the peripheral visual field. The possible 
responses were “yes” or “no”.
Statistical Analysis
The primary study endpoint was to show statistically equal 
visual acuity outcomes between both study groups mea-
suring UDVA in photopic light conditions. For sample size 
calculation we used the Sealed Envelope Power 
Calculator18 and the following parameters: alpha = 0.05, 
power = 0.90, two-sided test, expected SD of outcome = 
0.08 logMAR (based on our experience from former POD 
F studies), equivalence limit = four optotypes of a Snellen 
line (=0.08 logMAR). In order to show no difference 
between the two study cohorts, 22 patients per group 
were needed.
To assess whether the results of the NEI VFQ-25 
questionnaire correlated with visual acuity, contrast sensi-
tivity and halometry discrimination index, a Spearman 
correlation analysis was performed, based on the overall 
composite score obtained from the VFQ-25.
Statistical data analysis was performed using Microsoft 
Excel (version 16.0) including the add-in statistics soft-
ware WinSTAT (version 2012.1.0.96). Results of descrip-
tive statistics are expressed as mean (± standard deviation) 
and median (range). The Mann–Whitney U-test was used 
to assess the significance of differences between groups. 
The Wilcoxon rank-sum test for paired data was per-
formed to assess the significance of differences between 
examinations. A p-value of less than 0.05 was considered 
statistically significant. The refractive prediction error was 
calculated by subtracting the postoperative manifest sphe-
rical equivalent (SE) from the preoperative targeted SE 
given by the IOLMaster.
Results
A total of 51 patients (POD F GF group: 26; POD F group: 
25) were recruited for this study. All patients were available 
for follow-up at 1 month, and 49 patients (POD F GF group: 
25; POD F group: 24) completed the 3-month follow-up 
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examination. The patients’ mean age (SD, range) on the day 
of surgery was 65.0 (6.3, 47.1–75.2) years and 66.0 (6.9, 
52.7–83.7) years in the POD F and POD F GF groups, 
respectively. The majority of patients in both treatment 
groups were female: 21/25 (84.0%) and 23/26 (88.5%) in 
the POD F and POD F GF groups, respectively (Table 1). 
There was no statistically significant difference in patient 
age (p=0.553) and preoperative biometry and keratometry 
values between the two treatment groups (p>0.05) (Table 2).
Patients bilaterally implanted with either lens showed post-
operative visual outcomes as follows. At the 3-month follow- 
up, mean (SD) values for binocular UDVA, CDVA, DCIVA 
(80 cm), and DCNVA (40 cm) were −0.01 (0.06), −0.04 
(0.04), 0.09 (0.10) and 0.10 (0.09) logMAR, respectively, for 
POD F, and 0.01 (0.08), −0.03 (0.03), 0.08 (0.1) and 0.13 
(0.11) respectively, for POD F GF. Additionally, at 3 months, 
95.8% (POD F, n=23) and 100% (POD F GF, n=24) of each 
treatment group experienced vision of 0.1 logMAR (20/25) or 
better for binocular UDVA and CDVA (Figure 1A and B). 
Good binocular DCIVA (≤0.1 logMAR) at 3 months was also 
obtained; 75.0% (POD F, n=18) and 79.2% (POD F GF, 
n=19), and 92.0% (POD F, n=23) and 88.0% (POD F GF, 
n=22) for DCIVA at 80 cm (3 months) and 70 cm (1 month) 
respectively (Figure 1C and D); at near, these values were 
83.3% (POD F, n=20) and 70.8% (POD F GF, n=17), and 
88.0% (n=22) for both POD F and POD F GF, for DCNVA at 
40 cm (Radner, 3 months) and at 35 cm (ETDRS, 1 month) 
respectively (Figure 1E and F). Overall, mean visual acuity 
(VA) outcomes were very good for all distances down to 
35 cm in both study groups (Figure 1G). There was no statis-
tically significant difference in VA between the two treatment 
groups at any of these distances (p>0.05).
The binocular defocus curve analysis (Figure 2) showed 
an extended range of clear vision rather than distinct peaks 
corresponding to the +1.75 D and +3.50 D adds for each IOL 
design. Between the foci for distance and near vision (for 
defocus levels between 0.0 and −3.0 D), a functional range of 
visual acuity was maintained, with mean values of 0.09 
logMAR (20/25) or better in the POD F group and 0.15 
logMAR (20/28) or better in the POD F GF group. In effect 
the defocus curves were not significantly different, except for 
at one defocus value of −3 D where the POD F lens showed 
significantly higher VA than the POD F GF lens (p=0.017).
Table 1 Patient Demographics and IOL Power per Group
POD F POD F GF
Gender (n, %)
Female 21, 84.0 23, 88.5













Abbreviations: IOL, intraocular lens; n, number; SD, standard deviation; Min, 
minimum; Max, maximum; D, diopter.
Table 2 Preoperative Biometry and Keratometry Values
POD F POD F GF
AL (mm) ACD 
(mm)
K2 (D) Corneal 
Astigmatism 
(D)
AL (mm) ACD 
(mm)
K2 (D) Corneal 
Astigmatism 
(D)
Mean 23.34 3.04 43.82 −0.48 23.28 3.05 43.70 −0.56
SD 0.84 0.25 1.85 0.30 0.77 0.49 1.29 0.35
Median 23.48 3.05 43.97 −0.43 23.18 3.00 43.76 −0.55
Min 21.23 2.53 39.07 −1.36 21.81 2.04 41.55 −1.46
Max 24.74 3.43 47.93 0.00 25.08 4.29 47.24 0.00
N (eyes) 50 50 50 50 52 52 52 52
95% CI [23.11;23.57] [2.97;3.11] [43.31;44.33] [−0.56;-0.40] [23.07;23.49] [2.92;3.18] [43.35;44.05] [−0.66;-0.46]
P values* 0.505 0.820 0.441 0.228 - - - -
Note: *Difference between each group. 
Abbreviations: AL, axial length; ACD, anterior chamber depth; K2, corneal curvature of steepest meridian; SD, standard deviation; Min, minimum; Max, maximum; N, 
number; CI, confidence interval.
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Figure 1 Visual acuity results at 3 months. Cumulative binocular UDVA (A), CDVA (B), DCIVA at 80 cm (C) and 70 cm (D), DCNVA at 40 cm (E) and 35 cm (F), and (G) 
mean binocular values for all outcomes presented in (A–F). 
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; DCIVA, distance-corrected intermediate visual acuity; DCNVA, 
distance-corrected near visual acuity.
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The refractive outcomes of the patients involved in the 
trial are displayed in Figure 3. In terms of sphere, the 
refractive outcomes were similar in both groups (Figure 
3A), although the mean postoperative sphere was closer to 
zero in the POD F group. There was a statistically signifi-
cant reduction of refractive cylinder with POD F between 1 
week and 1 month (Figure 3B, p=0.032). The only signifi-
cant difference between the groups’ cylinder was measured 
at 1 month (p=0.020). Postoperative mean manifest refrac-
tion spherical equivalent (MRSE) (Figure 3C) was on target 
with POD F (0.00 ± 0.29D) and there were slightly hypero-
pic outcomes with POD F GF (mean MRSE = 0.23 D at 3 
months). Again, the only statistically significant difference 
between the groups was at 1 month (p=0.037). A slight but 
statistically non-significant (p>0.05) hyperopization was 
seen with POD F GF between 1 week and 3 months. At 3 
months, 83% (POD F, n=40) and 90% (POD F GF, n=45) 
of the eyes were within ±0.5D, and 100% (POD F, n=48) 
and 92% (POD F GF, n=46) were within ±1.0D of targeted 
refractive SE.
The results presented in Figure 4A–F reveal that there 
was no significant difference in halometry, modulation trans-
fer function, Strehl ratio, tilt, root-mean-square (RMS) 
HOAs (total, corneal or internal), spherical aberrations or 
photopic contrast sensitivity between the POF F and POF 
GF groups. Both lens groups exhibited low OSI scores. The 
photopic results were slightly better than the mesopic data at 
high and low spatial frequencies (Figure 4G and H). The 
mesopic curve of the POD F group at 3 and 6 cpd was 
slightly above the curve of the POD F GF group; however, 
the differences were not statistically significant (p>0.05). In 
terms of negative dysphotopsias (Figure 5), about one in 
three patients in both treatment groups reported these at day 
1 post-surgery, but the proportion of patients reporting this 
reduced to one out of eight (12.5%) in the POD F group, and 
to zero in the POD F GF group after 1 month – there was no 
Figure 2 Binocular defocus curve measured at 3 months postoperatively in the 
POD F and POD F GF group.
Figure 3 Pre- and postoperative refractive outcomes of sphere (A), cylinder (B) and MRSE (C) (% of eyes). 
Abbreviations: MRSE, manifest refraction spherical equivalent; M, months, W, week.
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Figure 4 Halometry at 3 months (A), MTF at 1 week and 3 months (B), Strehl ratio at 1 week and 3 months (C), tilt at 1 month (D), HOA RMS at 1 month (E), spherical 
aberrations (F) and binocular photopic (G) and mesopic (H) contrast sensitivity (logCS) at 3 months per group.
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statistically significant difference in negative dysphotopsia 
rates between each treatment group (p>0.05). The VFQ-25 
questionnaire revealed no significant difference between 
study groups (p>0.05) (Figure 6); both the POD F and 
POD F GF lenses scored very highly across all categories.
The results of a Spearman correlation analysis of VFQ-25 
total score versus VA, contrast and halometry indicated no 
significant correlations in the POD F group, but some (bino-
cular UDVA and CDVA; Patch A and D at 85 cd/m2; and 
Patch A at 6 cd/m2) were seen in the POD F GF group 
(Table 3).
After 3 months, a detailed slit-lamp examination was 
performed. Three eyes (2.9%) from two patients (one per 
treatment group) showed PCO classified as “mild” but no 
Nd:YAG treatment was needed. Dry eye was diagnosed in 
six eyes (5.9%) of three patients (four in the POD F group, 
two in the POD F GF group). Three eyes (2.9%) of three 
patients (two patients from the POD F group, one from the 
POD F GF group) developed posterior vitreous detach-
ment (PVD) at 3 months after surgery; one patient (POD 
F group) developed bilateral (1.96%) PVD at 1 month. No 
anterior capsular fibrosis was detected in any case.
Figure 5 Negative dysphotopsia at the 1-day (1D), 1-week (1W) and 1-month (1M) visit of the POD F group (A) and the POD F GF group (B).
Figure 6 Results of VFQ-25 questionnaire for each group conducted 3 months after surgery.
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Discussion
The FineVision POD F lens has repeatedly been shown in 
clinical trials to restore vision at various distances follow-
ing cataract surgery, specifically intermediate and near 
vision.8–14 In the past, the FineVision optical design has 
also proven its effectiveness in numerous clinical studies 
with the hydrophilic Micro F IOL model (PhysIOL, Liége, 
Belgium).13,14,19–25 Unlike double-C-loop POD lenses, the 
Micro F IOL has a four-loop haptic design. Compared to 
extended depth of focus (EDOF) lenses, FineVision IOLs 
performed statistically significantly better in terms of 
uncorrected near vision.19,21 Furthermore, compared to 
bifocal lenses, the trifocal FineVision optic design allows 
for a higher degree of complete spectacle independence.25
This study demonstrated that the trifocal IOLs, POD 
F and POD F GF provided equally good unaided functional 
vision at far, intermediate and near distances, under both 
photopic and mesopic conditions, following binocular 
implantation in patients undergoing cataract surgery. Both 
lenses effectively and predictably reduced refractive errors, 
and our study found no disadvantages associated with the 
hydrophobic biomaterial used in the POD F GF lens.
Overall, our findings are in line with the recently 
published outcomes of Nagy et al.9 This prospective 
study compared the clinical outcomes of patients 
undergoing cataract surgery and implantation of POD 
F in one eye and POD F GF in the contralateral eye. The 
authors reported that 6 months after surgery there was no 
statistically significant difference in monocular distance, 
intermediate and near visual acuities, or contrast sensitiv-
ity under photopic and mesopic conditions.9 In the POD 
F GF group, mean logMAR monocular photopic UDVA, 
CDVA, DCIVA, and DCNVA at 6 months was 0.00±0.07, 
−0.04±0.08, 0.04±0.09, and 0.04±0.07, respectively. The 
POD F group showed mean logMAR values of 0.03±0.12 
(UDVA), −0.04±0.09 (CDVA), 0.06±0.09 (DCIVA), and 
0.08±0.08 (DCNVA).9 Summarizing the outcomes, which 
are presented in a meta-analysis of trifocal IOLs, mean 
monocular UDVA from 9 studies (n=344 eyes) was 0.03 
logMAR.26 The review of another meta-analysis with tri-
focal lenses showed that the mean UDVA from 3 studies 
(n=81) was 0.07 logMAR, mean CDVA from 4 studies 
(n=105) was 0.01 logMAR, and mean DCNVA from 5 
studies (n=149) was 0.11 logMAR.27
Interestingly, in our study, both the binocular defocus 
curve as well as binocular DCNVA showed a trend 
towards a better near VA in the POD F group. However, 
the difference between both groups was only statistically 
significant in the defocus curve at −3 D, which corre-
sponds to the near vision. Furthermore, although not 
Table 3 Correlation Analysis (Spearman): VFQ Total Score vs Visual Acuity, vs Contrast, and vs Halometry in Both Groups
POD F POD F GF
R p-value R2 R′ p-value R2
VFQ total score vs visual acuity
Binocular UDVA (logMAR) −0.379 0.068 0.144 −0.427* 0.038 0.182
Binocular CDVA (LogMAR) −0.365 0.080 0.133 −0.435* 0.035 0.189
Binocular DCIVA 80 cm (LogMAR) −0.174 0.416 0.030 −0.079 0.714 0.006
Binocular DCNVA 40 cm (LogMAR) 0.159 0.457 0.025 −0.345 0.100 0.119
VFQ total score vs contrast sensitivity
Patch A 85 cd/m2 0.134 0.532 0.018 0.576* 0.004 0.332
Patch B 85 cd/m2 0.155 0.469 0.024 0.300 0.154 0.090
Patch C 85 cd/m2 0.217 0.306 0.047 0.051 0.815 0.003
Patch D 85 cd/m2 0.068 0.751 0.005 0.442* 0.032 0.195
Patch A 6 cd/m2 0.289 0.170 0.084 0.410* 0.047 0.168
Patch B 6 cd/m2 0.373 0.074 0.139 0.108 0.615 0.012
Patch C 6 cd/m2 0.151 0.481 0.023 −0.211 0.320 0.045
Patch D 6 cd/m2 0.342 0.102 0.117 −0.184 0.389 0.034
VFQ total score vs discrimination index
Halometry Discrimination Index (linear) 1 m −0.090 0.674 0.008 0.321 0.126 0.103
Note: *Significantly different from zero (p<0.05). 
Abbreviations: VFQ, Visual Function Questionnaire; R, correlation coefficient; R2, coefficient of determination; UDVA, uncorrected distance visual acuity; CDVA, 
corrected distance visual acuity; DCIVA, distance-corrected intermediate visual acuity, DCNVA, distance-corrected near visual acuity.
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statistically significant, the mesopic contrast sensitivity of 
the POD F group at 3 and 6 cpd was slightly better than in 
the hydrophobic group. These findings are not consistent 
with recently published data where the authors reported no 
statistically significant difference between POD F and 
POD F GF regarding the monocular photopic defocus 
curve.9 Also, mesopic contrast sensitivity in this study 
was almost identical or even slightly better for POD 
F GF at 3 cpd.9
Multifocal IOLs do involve optical compromises, and 
one of the factors that can be compromised with such 
designs is contrast sensitivity; in this trial, as expected, 
both lenses’ mesopic results were slightly worse than their 
photopic results at high and low spatial frequencies. 
Another potential consequence of multifocal IOL optics 
is an increase in photic phenomena, but in the case of both 
the POD F and POD F IOLs, halometry results showed 
that neither lens appeared to introduce any additional 
problems to those reported for diffractive IOL designs. 
Single-piece hydrophobic acrylic high-refractive-index 
IOLs have been associated with higher rates of postopera-
tive negative dysphotopsias,28 but best-practice placement 
of the optic-haptic junction, as was observed in this study, 
can help reduce these rates.16 It was therefore encouraging 
to observe that at 1 month postoperatively, there were no 
reports of negative dysphotopsia in patients implanted 
with the hydrophobic acrylic POD F GF IOL.
The MTF and Strehl Ratio were close to that of 
a normal population, and tilt, HAO and spherical aberra-
tions were similar for both IOL models. The OSI was low 
in both groups and did not differ statistically significantly 
between the lenses.
In our study, no glistenings were observed in either 
group and there was no clinically relevant PCO over the 
follow-up time necessitating Nd:YAG posterior capsulot-
omy. This is consistent with the results of Nagy et al, who 
observed neither glistening nor significant PCO over 
a follow-up period of 6 months for POD F and POD 
F GF IOLs.9
Overall, this study showed that both lenses exhibited 
very satisfactory visual outcomes over a 3-month follow- 
up period, and that both the POD F and POD F GF lenses 
are essentially equivalent in visual outcomes at 1 and 3 
months after implantation. Patient satisfaction scores, as 
assessed by the VFQ-25 questionnaire, were very high and 
similar in both lenses.
This study had some limitations; a relatively small 
study size and a final follow-up period of 3 months. 
A longer follow-up period of at least 6 months – particu-
larly in relation to detecting the development of significant 
PCO and glistenings, none of which were observed in this 
trial, and which can take years to form – and a larger 
sample size would enable a more comprehensive assess-
ment of lens performance.
Conclusion
In conclusion, this study demonstrated good visual and 
refractive outcomes with the new hydrophobic POD F GF 
lens compared with the existing hydrophilic POD F lens. 
Both IOLs allow for safe and efficient restoration of near, 
intermediate, and distance visual acuity for cataract patients 
undergoing IOL implantation. The introduction of 
a hydrophobic, glistening-free version of the established 
FineVision POD F trifocal design, and the knowledge that 
the FineVision POD F GF optics are essentially functionally 
equivalent to POD F, means that surgeons now have the 
option to choose this new material with a familiar optical 
design. This may become the lens of choice for patients 
where the benefits of a reduced risk of PCO and glistenings 
in the longer term are important considerations.
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